PROF · Profound Medical Corp.

This 8-K filing conveys a strategic clinical and technological advancement rather than a financial or governance event. The four AUA2026 oral presentations—by investigators from Mayo Clinic, Turku University Hospital, and Sapporo Hokuyu Hospital—collectively reinforce clinical evidence across geographies and study designs: multicenter registry data, phase 2 trial results, real-world outcomes, and insights on neoadjuvant therapy interactions. These presentations strengthen the clinical credibility of TULSA as a flexible, MRI-guided ablation platform. The PSMA PET integration initiative represents a forward-looking step toward precision oncology workflows, explicitly aiming to augment treatment planning—not patient selection—by combining molecular imaging with TULSA’s real-time, anatomy-adaptive ablation capability. Management commentary underscores that this is about empowering physicians to confidently deliver focal, subtotal, or whole-gland intent-to-treat strategies tailored per patient. While no financial metrics, regulatory approvals, or commercial milestones are disclosed, the timing and venue (AUA—the premier urology conference) signal targeted engagement with key opinion leaders and potential adopters. The disclosure also includes important contextual limitations, such as the unconfirmed U.S. availability of TULSA-PRO on low-field MRI systems, which tempers near-term commercial expectations for that specific configuration.